Skip to content
AnalystLens

Bunge Global 8-K Report, Financial Results (Feb 5, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 5, 2025
Period End
February 5, 2025
Security
BG
In the record · 2023–202610-K310-Q98-K60

BG filed 3 annual reports (10-K), 9 quarterly reports (10-Q) and 60 current reports (8-K) between 2023 and 2026.

  1. Leadership change8-K · May ’24May ’24
  2. Deal closed8-K · Jul ’25Jul ’25
  3. Material agreement8-K · Nov ’26Nov ’26

01—Abstract

Summary

Summary of the 8-K filed February 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Bunge Global SA (NYSE: BG) reported fourth-quarter and full-year 2024 results on February 5, 2025, with a clear earnings decline.

Full-year GAAP diluted EPS fell to $7.99a from $14.87, and adjusted EPS (excluding mark-to-market timing differences and certain gains/charges) fell to $9.19 from $13.66. Q4 GAAP diluted EPS was $4.36 versus $4.18, but adjusted Q4 EPS dropped to $2.13 from $3.70. Core Segment EBIT declined to $2.17 billion from $3.72 billion for the year, driven mainly by lower Agribusiness Processing results in North America and lower Refined and Specialty Oils results, particularly in North America.

Management attributed the weakness to a more balanced supply-demand environment and uncertainty around U.S. biofuel policy, and acknowledged that results did not meet its expectations. Balance sheet and cash flow showed pressure. Operating cash flow fell to $1.9 billionb from $3.3 billion, and adjusted funds from operations declined to $1.68 billion from $2.47 billion.

Bunge still repurchased $1.1 billionc of shares for the year, including $500 million in Q4, and ended the year with $3.3 billion in cash. Gross debt rose, with long-term debt increasing to $4.69 billion from $4.08 billion, and total equity declined. Non-core results were supported by a $195 million one-time gain from the sale of its 50% stake in the BP Bunge Bioenergia sugar and bioenergy joint venture, completed October 1, 2024.

Looking ahead, Bunge forecast full-year 2025 adjusted EPS of approximately $7.75d, below 2024 adjusted EPS of $9.19, and guided to lower Agribusiness and Refined and Specialty Oils results, with Milling and Corporate and Other expected to improve. The outlook excludes announced acquisitions, notably the pending Viterra combination, which management said is in late stages of regulatory approval and expected to close soon. Forward visibility was described as limited given heightened geopolitical uncertainty.

02—Key points

Key Highlights

  1. Full-year 2024 GAAP diluted EPS fell 46% to $7.99 from $14.87; adjusted EPS fell 33% to $9.19 from $13.66.
  2. Core Segment EBIT dropped to $2.17 billion from $3.72 billion, led by lower Agribusiness Processing results and weaker North American refined oils margins.
  3. Operating cash flow fell to $1.9 billion from $3.3 billion, and adjusted FFO declined to $1.68 billion from $2.47 billion.
  4. 2025 guidance calls for adjusted EPS of about $7.75, below 2024's $9.19, with lower Agribusiness and Refined and Specialty Oils results expected.
  5. A $195 million one-time gain on the sale of the BP Bunge Bioenergia stake supported Non-core results and GAAP EPS; the sale was completed October 1, 2024.
  6. Bunge repurchased $1.1 billion of shares in 2024, including $500 million in Q4, while long-term debt rose to $4.69 billion from $4.08 billion.
  7. The pending Viterra combination is in late regulatory stages; 2025 guidance excludes announced acquisitions, so closing would change the outlook.

03—Questions

Frequently Asked Questions

  1. Why did Bunge's earnings decline significantly in 2024?

    Core Segment EBIT fell to $2.17 billion from $3.72 billion, mainly due to lower Processing results in North America and South America and lower Refined and Specialty Oils results driven by North America. Management cited a more balanced supply and demand environment and uncertainty around U.S. biofuel policies.

  2. What is Bunge's 2025 earnings outlook?

    Bunge forecasts full-year 2025 adjusted EPS of approximately $7.75, compared with $9.19 in 2024. Agribusiness and Refined and Specialty Oils results are expected to decline, while Milling and Corporate and Other are expected to improve. The forecast excludes announced acquisitions expected to close during the year.

  3. Did the Sugar & Bioenergy sale materially affect 2024 results?

    Yes, but only on a GAAP basis. Bunge recorded a $195 million gain on selling its 50% stake in BP Bunge Bioenergia, which lifted GAAP EPS. The gain is excluded from adjusted EPS, and the business contributed only about one month of income in 2024.

  4. How is Bunge's cash position and capital return?

    Operating cash flow fell to $1.9 billion from $3.3 billion, and adjusted FFO declined to $1.68 billion. Despite this, Bunge repurchased $1.1 billion of shares in 2024 and paid $378 million in dividends, while ending the year with $3.3 billion in cash and cash equivalents. Long-term debt increased to $4.69 billion.

  5. What is the status of the Viterra transaction?

    Management said Bunge has received the vast majority of required regulatory approvals and expects the Viterra combination to close soon. Acquisition and integration costs related to the deal were $243 million for 2024, which weighed on GAAP results and is excluded from adjusted figures.

04—Continue

← View all 8-K filings